Variation in urinary excretion of FDG, yet another uncertainty in quantitative PET

Acta Radiologica Short Reports

Tore Bach-Gansmo³  JA Dybvik¹  TC Adamsen²  A Naum² 

[1] Faculty of Medicine and Dentistry

[2] Center for Nuclear Medicine/PET

[3] Oslo University Hospital,

关键词: molecular imaging;    tissue characterization;    PET;   

Others  :  923575
DOI  :  10.1258/arsr.2012.120038

 received in 2012-07-23, accepted in 2012-09-05,  发布年份 2012

【 摘 要 】

Background The standardized uptake value (SUV) is the most common estimate of metabolic activity used in clinical positron emissiontomography (PET). Several biological and technological factors influence the accurate SUV calculation.

Purpose To assess another potential source of variability of the SUV, the variations in urinary excretion of fluorodeoxyglucose (FDG).

Material and Methods Twenty patients with various malignancies scheduled for PET/CT with 18F-FDG were included in the present study. The activityin urine voided immediately before image acquisition was measured and decay corrected. An estimation of FDG content in theurinary bladder was made during imaging, and the two components of urinary FDG were added. The urinary output of FDG, andthe quantity of FDG divided by the time to measurements, was estimated.

Results The excretion of FDG in urine was between 5.7% and 15.2% of injected dose (decay corrected), and from 0.06% to 0.3%/min afterinjection, a five-fold difference in clearance.

Conclusion About 10% of injected dose is excreted in urine at 70 min post injection, but the urinary FDG excretion was found to be highlyvariable, yet another uncertainty affecting the SUV measurements.

【 授权许可】

   
© 2012 The Foundation Acta Radiologica

【 参考文献 】

• [1]DiChiro G, Brooks RA DiChiro G, Brooks RA. PET quantitation: blessing and curse. J Nucl Med 1988;29:1603
• [2]Boellaard R Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50 (Suppl. 1):11S–20S
• [3]Hoekstra CJ, Hoekstra OS, Stroobants SG Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non–small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43:1304–9
• [4]Westerterp M, Pruim J, Oyen W Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007;34:392–404
• [5]Hoekstra CJ, Paglianiti I, Hoekstra OS Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [F-18]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731–43
• [6]Weber WA Weber WA. Chaperoning drug development with PET. J Nucl Med 2006;47:735–7